OrganiGram Holdings Net Income
| OGI Stock | USD 1.53 0.05 3.38% |
As of the 6th of February, OrganiGram Holdings holds the Variance of 16.66, insignificant risk adjusted performance, and Coefficient Of Variation of (7,144). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of OrganiGram Holdings, as well as the relationship between them.
OrganiGram Holdings Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.0268 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -22.3 M | -23.4 M | |
| Net Loss | -22.3 M | -23.4 M | |
| Net Loss | -206.5 M | -196.2 M | |
| Net Loss | (0.18) | (0.19) | |
| Net Income Per E B T | 0.99 | 0.70 |
OrganiGram | Net Income | Build AI portfolio with OrganiGram Stock |
The Net Income trend for OrganiGram Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether OrganiGram Holdings is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest OrganiGram Holdings' Net Income Growth Pattern
Below is the plot of the Net Income of OrganiGram Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in OrganiGram Holdings financial statement analysis. It represents the amount of money remaining after all of OrganiGram Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is OrganiGram Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OrganiGram Holdings' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
OrganiGram Net Income Regression Statistics
| Arithmetic Mean | (35,757,727) | |
| Coefficient Of Variation | (185.38) | |
| Mean Deviation | 46,911,540 | |
| Median | (10,890,000) | |
| Standard Deviation | 66,286,301 | |
| Sample Variance | 4393.9T | |
| Range | 250M | |
| R-Value | (0.36) | |
| Mean Square Error | 4078.7T | |
| R-Squared | 0.13 | |
| Significance | 0.16 | |
| Slope | (4,728,413) | |
| Total Sum of Squares | 70302T |
OrganiGram Net Income History
Other Fundumenentals of OrganiGram Holdings
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
OrganiGram Holdings Net Income component correlations
OrganiGram Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for OrganiGram Holdings is extremely important. It helps to project a fair market value of OrganiGram Stock properly, considering its historical fundamentals such as Net Income. Since OrganiGram Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OrganiGram Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OrganiGram Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will OrganiGram introduce new products? Factors like these will boost the valuation of OrganiGram Holdings. Anticipated expansion of OrganiGram directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.14) | Revenue Per Share | Quarterly Revenue Growth 0.791 | Return On Assets | Return On Equity |
Investors evaluate OrganiGram Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating OrganiGram Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause OrganiGram Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between OrganiGram Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OrganiGram Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, OrganiGram Holdings' market price signifies the transaction level at which participants voluntarily complete trades.
OrganiGram Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to OrganiGram Holdings' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of OrganiGram Holdings.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in OrganiGram Holdings on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding OrganiGram Holdings or generate 0.0% return on investment in OrganiGram Holdings over 90 days. OrganiGram Holdings is related to or competes with Journey Medical, InfuSystems Holdings, Aurora Cannabis, Helius Medical, Cartesian Therapeutics, Orchestra BioMed, and Inventiva. Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada More
OrganiGram Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure OrganiGram Holdings' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess OrganiGram Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 26.45 | |||
| Value At Risk | (5.06) | |||
| Potential Upside | 7.65 |
OrganiGram Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for OrganiGram Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as OrganiGram Holdings' standard deviation. In reality, there are many statistical measures that can use OrganiGram Holdings historical prices to predict the future OrganiGram Holdings' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | (0.11) |
OrganiGram Holdings February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 2.91 | |||
| Coefficient Of Variation | (7,144) | |||
| Standard Deviation | 4.08 | |||
| Variance | 16.66 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 26.45 | |||
| Value At Risk | (5.06) | |||
| Potential Upside | 7.65 | |||
| Skewness | 1.27 | |||
| Kurtosis | 4.03 |
OrganiGram Holdings Backtested Returns
OrganiGram Holdings maintains Sharpe Ratio (i.e., Efficiency) of -0.011, which implies the firm had a -0.011 % return per unit of risk over the last 3 months. OrganiGram Holdings exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check OrganiGram Holdings' Coefficient Of Variation of (7,144), variance of 16.66, and insignificant Risk Adjusted Performance to confirm the risk estimate we provide. The company holds a Beta of 0.63, which implies possible diversification benefits within a given portfolio. As returns on the market increase, OrganiGram Holdings' returns are expected to increase less than the market. However, during the bear market, the loss of holding OrganiGram Holdings is expected to be smaller as well. At this point, OrganiGram Holdings has a negative expected return of -0.0449%. Please make sure to check OrganiGram Holdings' kurtosis, and the relationship between the maximum drawdown and day median price , to decide if OrganiGram Holdings performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.72 |
Almost perfect reverse predictability
OrganiGram Holdings has almost perfect reverse predictability. Overlapping area represents the amount of predictability between OrganiGram Holdings time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of OrganiGram Holdings price movement. The serial correlation of -0.72 indicates that around 72.0% of current OrganiGram Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.72 | |
| Spearman Rank Test | -0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
OrganiGram Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, OrganiGram Holdings reported net income of (24.76 Million). This is 107.25% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 104.34% higher than that of the company.
OrganiGram Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OrganiGram Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OrganiGram Holdings could also be used in its relative valuation, which is a method of valuing OrganiGram Holdings by comparing valuation metrics of similar companies.OrganiGram Holdings is currently under evaluation in net income category among its peers.
OrganiGram Holdings Institutional Holders
Institutional Holdings refers to the ownership stake in OrganiGram Holdings that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of OrganiGram Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing OrganiGram Holdings' value.| Shares | Susquehanna International Group, Llp | 2025-06-30 | 131 K | The Toronto-dominion Bank | 2025-06-30 | 87.6 K | Mariner Wealth Advisors Llc | 2025-06-30 | 72.4 K | Vontobel Holding Ltd. | 2025-06-30 | 69.8 K | Ubs Group Ag | 2025-06-30 | 58.4 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 43.4 K | Clear Harbor Asset Management, Llc | 2025-06-30 | 40 K | Toron Capital Markets Inc | 2025-06-30 | 37.1 K | Two Sigma Advisers, Llc | 2025-06-30 | 35.5 K | Tidal Investments Llc. | 2025-06-30 | 2.6 M | Renaissance Technologies Corp | 2025-06-30 | 1 M |
OrganiGram Fundamentals
| Return On Equity | -0.0656 | ||||
| Return On Asset | -0.0197 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 195.1 M | ||||
| Shares Outstanding | 134.46 M | ||||
| Shares Owned By Insiders | 30.16 % | ||||
| Shares Owned By Institutions | 7.59 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| Price To Earning | (79.96) X | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 0.77 X | ||||
| Revenue | 186.09 M | ||||
| Gross Profit | 90.22 M | ||||
| EBITDA | (14.76 M) | ||||
| Net Income | (24.76 M) | ||||
| Cash And Equivalents | 127.36 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 8.75 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.17 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | (4.3 M) | ||||
| Short Ratio | 1.27 X | ||||
| Earnings Per Share | (0.14) X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 1.14 K | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 199 M | ||||
| Total Asset | 403.67 M | ||||
| Retained Earnings | (437.07 M) | ||||
| Working Capital | 158.74 M | ||||
| Current Asset | 204.52 M | ||||
| Current Liabilities | 54.43 M | ||||
| Net Asset | 403.67 M |
About OrganiGram Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OrganiGram Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OrganiGram Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OrganiGram Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is there potential for Pharmaceuticals market expansion? Will OrganiGram introduce new products? Factors like these will boost the valuation of OrganiGram Holdings. Anticipated expansion of OrganiGram directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.14) | Revenue Per Share | Quarterly Revenue Growth 0.791 | Return On Assets | Return On Equity |
Investors evaluate OrganiGram Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating OrganiGram Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause OrganiGram Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between OrganiGram Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OrganiGram Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, OrganiGram Holdings' market price signifies the transaction level at which participants voluntarily complete trades.